It was the event for the ages, but I know that not everyone could attend.
I know we all struggle with being busy, and I genuinely feel bad if you missed this one. I’ve never had a response like this before…EVER.
To Watch the Replay of Kyle’s Option Rocket Webinar
You’ll receive your replay link in a few minutes.
—– Related —–
This book has helped thousands of other traders learn the basics of biotech, and how to easily spot winning trades.
Whether you are new trader or a 30-year veteran, this book will help you find stocks that are primed to make parabolic moves. These strategies are Kyle’s secret weapons that have help him net over $3 Million in profits…and they are all yours for free.
This is normally $97.00, but it’s yours FREE!
I took profits today on IDRA on some news that they are expanding their partnership with BMY. It was a nice piece of news before ASCO, and I’ll be looking to buy back shares tomorrow.
Biotech has slowed down here a bit – which is typical of this season. I’m watching intently for new names to add. Patience and timing is always key!
Catalyst Swing names (1 – 4 week holds) I am watching…
Idera Pharmaceuticals (IDRA)
Catalyst Dates: Phase 2 data due out June 4th and another Phase 2 data readout in June
Buy Zone: $1.75 to $1.95
Profit Zone: $2.20 or higher
Stop Zone: $1.70 or below
Aquinox Pharmaceuticals (AQXP)
Catalyst Dates: Phase 3 data due out in the third quarter
Buy Zone: $12.00 to $13.00
Profit Zone: $16.00 or higher
Stop Zone: $11.50 or below
Bellerophon Therapeutics (BLPH)
Catalyst Dates: Interim Phase 3 data release in the middle of 2018 (likely late June or July)
Buy Zone: $2.20 to $2.40
Profit Zone: $2.75 or higher
Stop Zone: $2.10 or below
Durect Corporation (DRRX)
Catalyst Dates: Advisory Committee meeting on June 26th, FDA Approval dates on July 28th and August 7th.
Buy Zone: $1.75 to $2.00
Profit Zone: $2.40 or higher
Stop Zone: $1.65 or below
Array BioPharma (ARRY)
Catalyst Dates: Phase 3 data due out June 20-23 FDA approval date of June 30 as well.
Buy Zone: $14.50 to $15.50
Profit Zone: $18.00 or higher
Stop Zone: $14.00 or below
Global Blood Therapeutics (GBT)
Catalyst Dates: Phase 3 data likely due out in June. Officially in the “first half”
Buy Zone: $46.00 to $48.00
Profit Zone: $54.00 or higher
Stop Zone: $44.00 or below
Pluristem Therapeutics (PSTI)
Catalyst Dates: Phase 2 data due out to be published in June.
Buy Zone: $1.30 to $1.45
Profit Zone: $1.80 or higher
Stop Zone: $1.20 or below
Marinus Pharmaceuticals (MRNS)
Catalyst Dates: Phase 2 data due out in the third quarter. Two other Phase 2 datas due out in the fourth quarter.
Buy Zone: $4.25 to $4.75
Profit Zone: $6.00 or higher
Stop Zone: $4.00 or below
Cytokinetics Incorporated (CYTK)
Catalyst Dates: Phase 2 data due out June 16
Buy Zone: $8.50 to $9.00
Profit Zone: $10.00 or higher
Stop Zone: $7.40 or below
Catalyst Dates: Phase 3 data due late June or early July
Buy Zone: $39.50 to $40.50
Profit Zone: $45.00 or higher
Stop Zone: $37.50 or below
Catalyst Biosciences (CBIO)
Catalyst Dates: Phase 2 data in July
Buy Zone: $26.50 to $28.50
Profit Zone: $33.00 or higher
Stop Zone: $25.00 or below
Pain Therapeutics (PTIE)
Catalyst Dates: Advisory Committee Meeting June 26th and FDA approval date of August 7th
Buy Zone: $7.50 to $8.25
Profit Zone: $9.50 or higher
Stop Zone: $7.00 or below
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.